A Phase 3 interventional study of BW430C (lamotrigine) in Bipolar Disorder, sponsored by GlaxoSmithKline. Completed at 52 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-04-04.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing lamotrigine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Lamotrigine · Bipolar Disorder.
Among the 33 studies testing lamotrigine in Bipolar Disorder, this one is the 15th largest by enrollment, is one of 4 that started in 2008, is one of 11 in phase 3, and was the 20th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 33 studies testing lamotrigine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Lamotrigine: first FDA approval 1994 (LAMICTAL). What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 72 across the 33 interventional studies. Of the 33 that completed or were terminated, 20 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 33 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
17 studies in Bipolar Disorder by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 17 finished, 6 (35%) have results posted.
Among the 17 studies in Bipolar Disorder by GlaxoSmithKline, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 10th registered.
GlaxoSmithKline’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing lamotrigine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 17 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779 (NCT00550407)), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Abstinence
Oral contraceptive, either combined or progestogen alone (except during the Dosage Adjustment Phase)
Injectable progestogen
Implants of levonorgestrel
Estrogenic vaginal ring (except during the Dosage Adjustment Phase)
Percutaneous contraceptive patches (except during the Dosage Adjustment Phase)
Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label
Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject
Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam / gel / film / cream / suppository)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
study drug
Drug: BW430C (lamotrigine)
lamotrigine 50mg/day-400mg/day
Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, which does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.
Time frame: From baseline (Week 0) until 2 weeks after the end of treatment (Week 54)
Number of Participants With the Indicated Clinical Laboratory Test Values for Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), and Lactate Dehydrogenase (LDH)
Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: ALP, ALT, AST, GGT, and LDH. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: ALP, 104-338 International Units per liter (IU/L); ALT, 5-45 IU/L; AST, 10-40 IU/L; GGT, Male: 0-79 IU/L, Female: 0-48 IU/L; LDH 120-245 IU/L.
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/Early Withdrawal (EW)
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Bilirubin and Creatinine at Weeks 0, 6, 16, 28, 40, and 52/EW
Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: total bilirubin and creatinine. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total bilirubin, 3.42-17.1 micromoles per liter (UMOL/L); creatinine, Male: 57.46-96.356 UMOL/L, Female: 40.664-72.488 UMOL/L.
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Calcium, Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea/Blood Urea Nitrogen (BUN) at Weeks 0, 6, 16, 28, 40, and 52/EW
Participants were evaluated for the following clinical laboratory parameters for blood chemistry at the indicated time points: electrolytes (calcium, chloride, potassium, sodium), cholesterol, triglycerides, and urea/BUN. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges (micromoles per liter \[MMOL/L\]): calcium, 2.0459-2.495; chloride, 98-108; potassium, 3.5-5; sodium, 135-145; cholesterol, 3.879-5.66334; triglycerides, 0.565-1.6837; urea/BUN, 2.856-7.14.
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Platelet Count and White Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW
Participants in the study were evaluated for the following clinical laboratory parameters of hematology at the indicated time points: platelet count and white blood cell count. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: platelet count, 140-379 GI (gibi; 10\^9) per liter (GI/L); white blood cell count, 3.5-9.7 GI/L.
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Total Protein, Hemoglobin, and Hematocrit at Weeks 0, 6, 16, 28, 40, and 52/EW
Participants in the study were evaluated for total protein, hemoglobin, and hematocrit at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total protein, 65-82 grams per liter (G/L); hemoglobin, Male: 136-183 G/L, Female: 112-152 G/L; hematocrit (proportion of 1), Male: 0.404-0.519, Female: 0.343-0.452.
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of Participants With Clinical Laboratory Test Values Out of the Normal Range and in the Normal Range for Red Blood Cell Count at Weeks 0, 6, 16, 28, 40, and 52/EW
Red blood cell count was measured in participants at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: red blood cell count, Male: 4.38-5.77 TI (tebi; 10\^12)/L, Female: 3.76-5.16 TI/L.
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Number of Participants in the Indicated Category for Urine Glucose, Urine Protein, and Urine Urobilinogen at Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Urine glucose, urine protein, and urine urobilinogen were measured in participants at the indicated time points. In this dipstick (qualitative) test, the level of glucose, protein, and urobilinogen in urine samples was recorded as negative (NEG \[-\]), trace (TRA \[+/-\]), 1+, 2+, 3+, 4+, and 5+ (the plus sign increases with a higher level of glucose, protein, or urobilinogen in the urine: 1+=slightly positive, 2+=positive, 3+=high positive, 4+=very high positive, 5+=more positive than 4+).
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Mean Systolic Blood Pressure and Diastolic Blood Pressure of Participants at Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Systolic and diastolic blood pressure was measured in participants at the indicated time points.
Time frame: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Mean Heart Rate of Participants at Week 0 (Baseline) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Heart rate was measured in participants at the indicated time points.
Time frame: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Mean Weight of Participants at Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
The weight of participants was recorded at the indicated time points.
Time frame: Baseline (Week 0) and Weeks 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Mean Body Mass Index (BMI) of All Participants at Week 0 (Baseline) and Weeks 6, 8, 12, 16, 20, 24, 28, 32,36, 40, 44, 48, and 52/EW
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.
Time frame: Baseline (Week 0) and Weeks 0, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Number of Participants With the Indicated Electrocardiogram (ECG) Findings at Weeks 0, 6, 28, and 52/EW
ECGs were recorded in participants at the indicated time points. ECG findings, as determined by the physicians, were reported as normal, abnormal but not clinically significant (NCS), abnormal but clinically significant (CS), and no result. Specific definitions of ECG categorizations were not provided; physicians were expected to apply reasonable standards of clinical judgment.
Time frame: Weeks 0, 6, 28, and 52/EW
Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. The number of participants with an assessment varied depending on the number of assessments completed at each visit (indicated time points).
Time frame: Weeks 0, 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Change From Baseline in the Clinical Global Impressions of Severity (CGI-S) Total Score at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. Change from baseline was calculated as the values at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (or EW) minus the baseline value (Week 0).
Time frame: Baseline (Week 0) and Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52/EW
Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW
The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill).
Time frame: Weeks 6, 16, 28, 40, and 52/EW
Change From Baseline in the Hamilton Rating Scale for Depression (HAM-D) Scale Total Score at Weeks 6, 16, 28, 40, and 52/EW
The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW
The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. For all items, 0 is the "best" rating and 4 or 8 is the "worst" rating. YMRS total score was computed as the sum of the scores for the 11 items on the scale. The possible total scores range from 0 (best) to 60 (worst).
Time frame: Weeks 6, 16, 28, 40, and 52/EW
Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 6, 16, 28, 40, and 52/EW
The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. YMRS total score (range of 0-60) was computed as sum of the scores for the 11 items on the scale. Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).
Time frame: Baseline (Week 0) and Weeks 6, 16, 28, 40, and 52/EW
Median Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection)
Pharmacokinetic (PK) samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.
Time frame: from Week 6 to Week 52/EW
Median Serum Lamotrigine 100 mg and 200 mg Concentration Among Participants With Concomitant Use of Inhibitor (at the Timing of Blood Sample Collection)
PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.
Time frame: from Week 6 to Week 52/EW
Median Serum Lamotrigine 25, 100, 125, 150, 200, 225, 300, and 400 mg Concentrations Among Participants Without Concomitant Use of Inhibitor and Inducer
PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.
Time frame: from Week 6 to Week 52/EW
| Milestone | Lamotrigine - Dosage Adjustment Phase | Lamotrigine - Long-term Administration Phase |
|---|---|---|
| Started | 92 | 0 |
| Completed | 85 | 0 |
| Not completed | 7 | 0 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Milestone | Lamotrigine - Dosage Adjustment Phase | Lamotrigine - Long-term Administration Phase |
|---|---|---|
| Started | 0 | 85 |
| Completed | 0 | 68 |
| Not completed | 0 | 17 |
| Withdrew: Adverse event | 0 | 7 |
| Withdrew: Physician decision | 0 | 7 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol-defined stopping criteria | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of medicinal product, which does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or causes its prolongation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. A complete list of all SAEs and AEs experienced in the study can be found in the SAE/AE section.
| participants | Lamotrigine |
|---|---|
| Participants with any SAE | 13 |
| Participants with any non-serious AE | 75 |
Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: ALP, ALT, AST, GGT, and LDH. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: ALP, 104-338 International Units per liter (IU/L); ALT, 5-45 IU/L; AST, 10-40 IU/L; GGT, Male: 0-79 IU/L, Female: 0-48 IU/L; LDH 120-245 IU/L.
| participants | Lamotrigine |
|---|---|
| ALP, High, Week 0; n=92 | 1 |
| ALP, Normal, Week 0; n=92 | 89 |
| ALP, Low, Week 0; n=92 | 2 |
| ALP, High, Week 6; n=84 | 2 |
| ALP, Normal, Week 6; n=84 | 82 |
| ALP, Low, Week 6; n=84 | 0 |
| ALP, High, Week 16; n=78 | 3 |
| ALP, Normal, Week 16; n=78 | 74 |
| ALP, Low, Week 16; n=78 | 1 |
| ALP, High, Week 28; n=77 | 1 |
| ALP, Normal, Week 28; n=77 | 76 |
| ALP, Low, Week 28; n=77 | 0 |
| ALP, High, Week 40; n=70 | 3 |
| ALP, Normal, Week 40; n=70 | 66 |
| ALP, Low, Week 40; n=70 | 1 |
| ALP, High, Week 52/EW; n=86 | 4 |
| ALP, Normal, Week 52/EW; n=86 | 81 |
| ALP, Low, Week 52/EW; n=86 | 1 |
| ALT, High, Week 0; n=92 | 6 |
| ALT, Normal, Week 0; n=92 | 86 |
| ALT, Low, Week 0; n=92 | 0 |
| ALT, High, Week 6; n=84 | 2 |
| ALT, Normal, Week 6; n=84 | 82 |
| ALT, Low, Week 6; n=84 | 0 |
| ALT, High, Week 16; n=78 | 3 |
| ALT, Normal, Week 16; n=78 | 75 |
| ALT, Low, Week 16; n=78 | 0 |
| ALT, High, Week 28; n=77 | 4 |
| ALT, Normal, Week 28; n=77 | 73 |
| ALT, Low, Week 28; n=77 | 0 |
| ALT, High, Week 40; n=70 | 3 |
| ALT, Normal, Week 40; n=70 | 67 |
| ALT, Low, Week 40; n=70 | 0 |
| ALT, High, Week 52/EW; n=86 | 3 |
| ALT, Normal, Week 52/EW; n=86 | 83 |
| ALT, Low, Week 52/EW; n=86 | 0 |
| AST, High, Week 0; n=92 | 3 |
| AST, Normal, Week 0; n=92 | 89 |
| AST, Low, Week 0; n=92 | 0 |
| AST, High, Week 6; n=84 | 2 |
| AST, Normal, Week 6; n=84 | 82 |
| AST, Low, Week 6; n=84 | 0 |
| AST, High, Week 16; n=78 | 2 |
| AST, Normal, Week 16; n=78 | 76 |
| AST, Low, Week 16; n=78 | 0 |
| AST, High, Week 28; n=77 | 2 |
| AST, Normal, Week 28; n=77 | 75 |
| AST, Low, Week 28; n=77 | 0 |
| AST, High, Week 40; n=70 | 3 |
| AST, Normal, Week 40; n=70 | 67 |
| AST, Low, Week 40; n=70 | 0 |
| AST, High, Week 52/EW; n=86 | 3 |
| AST, Normal, Week 52/EW; n=86 | 83 |
| AST, Low, Week 52/EW; n=86 | 0 |
| GGT, High, Week 0; n=92 | 5 |
| GGT, Normal, Week 0; n=92 | 87 |
| GGT, Low, Week 0; n=92 | 0 |
| GGT, High, Week 6; n=84 | 3 |
| GGT, Normal, Week 6; n=84 | 81 |
| GGT, Low, Week 6; n=84 | 0 |
| GGT, High, Week 16; n=78 | 4 |
| GGT, Normal, Week 16; n=78 | 74 |
| GGT, Low, Week 16; n=78 | 0 |
| GGT, High, Week 28; n=77 | 5 |
| GGT, Normal, Week 28; n=77 | 72 |
| GGT, Low, Week 28; n=77 | 0 |
| GGT, High, Week 40; n=70 | 4 |
| GGT, Normal, Week 40; n=70 | 66 |
| GGT, Low, Week 40; n=70 | 0 |
| GGT, High, Week 52/EW; n=86 | 5 |
| GGT, Normal, Week 52/EW; n=86 | 81 |
| GGT, Low, Week 52/EW; n=86 | 0 |
| LDH, High, Week 0; n=92 | 4 |
| LDH, Normal, Week 0; n=92 | 84 |
| LDH, Low, Week 0; n=92 | 4 |
| LDH, High, Week 6; n=84 | 4 |
| LDH, Normal, Week 6; n=84 | 77 |
| LDH, Low, Week 6; n=84 | 3 |
| LDH, High, Week 16; n=78 | 2 |
| LDH, Normal, Week 16; n=78 | 73 |
| LDH, Low, Week 16; n=78 | 3 |
| LDH, High, Week 28; n=77 | 3 |
| LDH, Normal, Week 28; n=77 | 72 |
| LDH, Low, Week 28; n=77 | 2 |
| LDH, High, Week 40; n=70 | 3 |
| LDH, Normal, Week 40; n=70 | 64 |
| LDH, Low, Week 40; n=70 | 3 |
| LDH, High, Week 52/EW; n=86 | 3 |
| LDH, Normal, Week 52/EW; n=86 | 82 |
| LDH, Low, Week 52/EW; n=86 | 1 |
Participants in the study were evaluated for the following clinical laboratory parameters at the indicated time points: total bilirubin and creatinine. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total bilirubin, 3.42-17.1 micromoles per liter (UMOL/L); creatinine, Male: 57.46-96.356 UMOL/L, Female: 40.664-72.488 UMOL/L.
| participants | Lamotrigine |
|---|---|
| Total bilirubin, High, Week 0; n=92 | 5 |
| Total bilirubin, Normal, Week 0; n=92 | 87 |
| Total bilirubin, Low, Week 0; n=92 | 0 |
| Total bilirubin, High, Week 6; n=84 | 5 |
| Total bilirubin, Normal, Week 6; n=84 | 79 |
| Total bilirubin, Low, Week 6; n=84 | 0 |
| Total bilirubin, High, Week 16; n=78 | 2 |
| Total bilirubin, Normal, Week 16; n=78 | 76 |
| Total bilirubin, Low, Week 16; n=78 | 0 |
| Total bilirubin, High, Week 28; n=77 | 3 |
| Total bilirubin, Normal, Week 28; n=77 | 74 |
| Total bilirubin, Low, Week 28; n=77 | 0 |
| Total bilirubin, High, Week 40; n=70 | 4 |
| Total bilirubin, Normal, Week 40; n=70 | 66 |
| Total bilirubin, Low, Week 40; n=70 | 0 |
| Total bilirubin, High, Week 52/EW; n=86 | 8 |
| Total bilirubin, Normal, Week 52/EW; n=86 | 78 |
| Total bilirubin, Low, Week 52/EW; n=86 | 0 |
| Creatinine, High, Week 0; n=92 | 2 |
| Creatinine, Normal, Week 0; n=92 | 86 |
| Creatinine, Low, Week 0; n=92 | 4 |
| Creatinine, High, Week 6; n=84 | 2 |
| Creatinine, Normal, Week 6; n=84 | 81 |
| Creatinine, Low, Week 6; n=84 | 1 |
| Creatinine, High, Week 16; n=78 | 4 |
| Creatinine, Normal, Week 16; n=78 | 72 |
| Creatinine, Low, Week 16; n=78 | 2 |
| Creatinine, High, Week 28; n=77 | 2 |
| Creatinine, Normal, Week 28; n=77 | 73 |
| Creatinine, Low, Week 28; n=77 | 2 |
| Creatinine, High, Week 40; n=70 | 2 |
| Creatinine, Normal, Week 40; n=70 | 66 |
| Creatinine, Low, Week 40; n=70 | 2 |
| Creatinine, High, Week 52/EW; n=86 | 3 |
| Creatinine, Normal, Week 52/EW; n=86 | 79 |
| Creatinine, Low, Week 52/EW; n=86 | 4 |
Participants were evaluated for the following clinical laboratory parameters for blood chemistry at the indicated time points: electrolytes (calcium, chloride, potassium, sodium), cholesterol, triglycerides, and urea/BUN. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges (micromoles per liter \[MMOL/L\]): calcium, 2.0459-2.495; chloride, 98-108; potassium, 3.5-5; sodium, 135-145; cholesterol, 3.879-5.66334; triglycerides, 0.565-1.6837; urea/BUN, 2.856-7.14.
| participants | Lamotrigine |
|---|---|
| Calcium, High, Week 0; n=92 | 1 |
| Calcium, Normal, Week 0; n=92 | 91 |
| Calcium, Low, Week 0; n=92 | 0 |
| Calcium, High, Week 6; n=84 | 4 |
| Calcium, Normal, Week 6; n=84 | 80 |
| Calcium, Low, Week 6; n=84 | 0 |
| Calcium, High, Week 16; n=78 | 2 |
| Calcium, Normal, Week 16; n=78 | 75 |
| Calcium, Low, Week 16; n=78 | 1 |
| Calcium, High, Week 28; n=77 | 1 |
| Calcium, Normal, Week 28; n=77 | 76 |
| Calcium, Low, Week 28; n=77 | 0 |
| Calcium, High, Week 40; n=70 | 1 |
| Calcium, Normal, Week 40; n=70 | 69 |
| Calcium, Low, Week 40; n=70 | 0 |
| Calcium, High, Week 52/EW; n=86 | 0 |
| Calcium, Normal, Week 52/EW; n=86 | 85 |
| Calcium, Low, Week 52/EW; n=86 | 1 |
| Cholesterol, High, Week 0; n=92 | 21 |
| Cholesterol, Normal, Week 0; n=92 | 66 |
| Cholesterol, Low, Week 0; n=92 | 5 |
| Cholesterol, High, Week 6; n=84 | 20 |
| Cholesterol, Normal, Week 6; n=84 | 57 |
| Cholesterol, Low, Week 6; n=84 | 7 |
| Cholesterol, High, Week 16; n=78 | 16 |
| Cholesterol, Normal, Week 16; n=78 | 58 |
| Cholesterol, Low, Week 16; n=78 | 4 |
| Cholesterol, High, Week 28; n=77 | 13 |
| Cholesterol, Normal, Week 28; n=77 | 61 |
| Cholesterol, Low, Week 28; n=77 | 3 |
| Cholesterol, High, Week 40; n=70 | 20 |
| Cholesterol, Normal, Week 40; n=70 | 45 |
| Cholesterol, Low, Week 40; n=70 | 5 |
| Cholesterol, High, Week 52/EW; n=86 | 18 |
| Cholesterol, Normal, Week 52/EW; n=86 | 64 |
| Cholesterol, Low, Week 52/EW; n=86 | 4 |
| Chloride, High, Week 0; n=92 | 2 |
| Chloride, Normal Week 0; n=92 | 90 |
| Chloride, Low, Week 0; n=92 | 0 |
| Chloride, High, Week 6; n=84 | 0 |
| Chloride, Normal, Week 6; n=84 | 84 |
| Chloride, Low, Week 6; n=84 | 0 |
| Chloride, High, Week 16; n=78 | 0 |
| Chloride, Normal, Week 16; n=78 | 77 |
| Chloride, Low, Week 16; n=78 | 1 |
| Chloride, High, Week 28; n=77 | 0 |
| Chloride, Normal, Week 28; n=77 | 76 |
| Chloride, Low, Week 28; n=77 | 1 |
| Chloride, High, Week 40; n=70 | 2 |
| Chloride, Normal, Week 40; n=70 | 66 |
| Chloride, Low, Week 40; n=70 | 2 |
| Chloride, High, Week 52/EW; n=86 | 3 |
| Chloride, Normal, Week 52/EW; n=86 | 79 |
| Chloride, Low, Week 52/EW; n=86 | 4 |
| Potassium, High, Week 0; n=92 | 0 |
| Potassium, Normal, Week 0; n=92 | 92 |
| Potassium, Low, Week 0; n=92 | 0 |
| Potassium, High, Week 6; n=84 | 1 |
| Potassium, Normal, Week 6; n=84 | 83 |
| Potassium, Low, Week 6; n=84 | 0 |
| Potassium, High, Week 16; n=78 | 2 |
| Potassium, Normal, Week 16; n=78 | 76 |
| Potassium, Low, Week 16; n=78 | 0 |
| Potassium, High, Week 28; n=77 | 0 |
| Potassium, Normal, Week 28; n=77 | 76 |
| Potassium, Low, Week 28; n=77 | 1 |
| Potassium, High, Week 40; n=70 | 2 |
| Potassium, Normal, Week 40; n=70 | 68 |
| Potassium, Low, Week 40; n=70 | 0 |
| Potassium, High, Week 52/EW; n=86 | 0 |
| Potassium, Normal, Week 52/EW; n=86 | 86 |
| Potassium, Low, Week 52/EW; n=86 | 0 |
| Sodium, High, Week 0; n=92 | 1 |
| Sodium, Normal, Week 0; n=92 | 90 |
| Sodium, Low, Week 0; n=92 | 1 |
| Sodium, High, Week 6; n=84 | 0 |
| Sodium, Normal, Week 6; n=84 | 83 |
| Sodium, Low, Week 6; n=84 | 1 |
| Sodium, High, Week 16; n=78 | 0 |
| Sodium, Normal, Week 16; n=78 | 77 |
| Sodium, Low, Week 16; n=78 | 1 |
| Sodium, High, Week 28; n=77 | 0 |
| Sodium, Normal, Week 28; n=77 | 76 |
| Sodium, Low, Week 28; n=77 | 1 |
| Sodium, High, Week 40; n=70 | 0 |
| Sodium, Normal, Week 40; n=70 | 69 |
| Sodium, Low, Week 40; n=70 | 1 |
| Sodium, High, Week 52/EW; n=86 | 1 |
| Sodium, Normal, Week 52/EW; n=86 | 83 |
| Sodium, Low, Week 52/EW; n=86 | 2 |
| Triglycerides, High, Week 0; n=92 | 23 |
| Triglycerides, Normal, Week 0; n=92 | 55 |
| Triglycerides, Low, Week 0; n=92 | 14 |
| Triglycerides, High, Week 6; n=84 | 20 |
| Triglycerides, Normal, Week 6; n=84 | 50 |
| Triglycerides, Low, Week 6; n=84 | 14 |
| Triglycerides, High, Week 16; n=78 | 20 |
| Triglycerides, Normal, Week 16; n=78 | 50 |
| Triglycerides, Low, Week 16; n=78 | 8 |
| Triglycerides, High, Week 28; n=77 | 23 |
| Triglycerides, Normal, Week 28; n=77 | 42 |
| Triglycerides, Low, Week 28; n=77 | 12 |
| Triglycerides, High, Week 40; n=70 | 18 |
| Triglycerides, Normal, Week 40; n=70 | 40 |
| Triglycerides, Low, Week 40; n=70 | 12 |
| Triglycerides, High, Week 52/EW; n=86 | 21 |
| Triglycerides, Normal, Week 52/EW; n=86 | 53 |
| Triglycerides, Low, Week 52/EW; n=86 | 12 |
| Urea/BUN, High, Week 0; n=92 | 4 |
| Urea/BUN, Normal, Week 0; n=92 | 77 |
| Urea/BUN, Low, Week 0; n=92 | 11 |
| Urea/BUN, High, Week 6; n=84 | 1 |
| Urea/BUN, Normal, Week 6; n=84 | 74 |
| Urea/BUN, Low, Week 6; n=84 | 9 |
| Urea/BUN, High, Week 16; n=78 | 5 |
| Urea/BUN, Normal, Week 16; n=78 | 68 |
| Urea/BUN, Low, Week 16; n=78 | 5 |
| Urea/BUN, High, Week 28; n=77 | 2 |
| Urea/BUN, Normal, Week 28; n=77 | 73 |
| Urea/BUN, Low, Week 28; n=77 | 2 |
| Urea/BUN, High, Week 40; n=70 | 5 |
| Urea/BUN, Normal, Week 40; n=70 | 56 |
| Urea/BUN, Low, Week 40; n=70 | 9 |
| Urea/BUN, High, Week 52/EW; n=86 | 5 |
| Urea/BUN, Normal, Week 52/EW; n=86 | 74 |
| Urea/BUN, Low, Week 52/EW; n=86 | 7 |
Participants in the study were evaluated for the following clinical laboratory parameters of hematology at the indicated time points: platelet count and white blood cell count. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: platelet count, 140-379 GI (gibi; 10\^9) per liter (GI/L); white blood cell count, 3.5-9.7 GI/L.
| participants | Lamotrigine |
|---|---|
| Platelet count, High, Week 0; n=92 | 3 |
| Platelet count, Normal, Week 0; n=92 | 89 |
| Platelet count, Low, Week 0; n=92 | 0 |
| Platelet count, High, Week 6; n=84 | 2 |
| Platelet count, Normal, Week 6; n=84 | 81 |
| Platelet count, Low, Week 6; n=84 | 1 |
| Platelet count, High, Week 16; n=78 | 2 |
| Platelet count, Normal, Week 16; n=78 | 75 |
| Platelet count, Low, Week 16; n=78 | 1 |
| Platelet count, High, Week 28; n=77 | 2 |
| Platelet count, Normal, Week 28; n=77 | 75 |
| Platelet count, Low, Week 28; n=77 | 0 |
| Platelet count, High, Week 40; n=68 | 0 |
| Platelet count, Normal, Week 40; n=68 | 68 |
| Platelet count, Low, Week 40; n=68 | 0 |
| Platelet count, High, Week 52/EW; n=86 | 3 |
| Platelet count, Normal, Week 52/EW; n=86 | 82 |
| Platelet count, Low, Week 52/EW; n=86 | 1 |
| White blood cell count, High, Week 0; n=92 | 7 |
| White blood cell count, Normal, Week 0; n=92 | 83 |
| White blood cell count, Low, Week 0; n=92 | 2 |
| White blood cell count, High, Week 6; n=84 | 1 |
| White blood cell count, Normal, Week 6; n=84 | 81 |
| White blood cell count, Low, Week 6; n=84 | 2 |
| White blood cell count, High, Week 16; n=78 | 1 |
| White blood cell count, Normal, Week 16; n=78 | 75 |
| White blood cell count, Low, Week 16; n=78 | 2 |
| White blood cell count, High, Week 28; n=77 | 2 |
| White blood cell count, Normal, Week 28; n=77 | 70 |
| White blood cell count, Low, Week 28; n=77 | 5 |
| White blood cell count, High, Week 40; n=69 | 3 |
| White blood cell count, Normal, Week 40; n=69 | 61 |
| White blood cell count, Low, Week 40; n=69 | 5 |
| White blood cell count, High, Week 52/EW; n=86 | 3 |
| White blood cell count, Normal, Week 52/EW; n=86 | 80 |
| White blood cell count, Low, Week 52/EW; n=86 | 3 |
Participants in the study were evaluated for total protein, hemoglobin, and hematocrit at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: total protein, 65-82 grams per liter (G/L); hemoglobin, Male: 136-183 G/L, Female: 112-152 G/L; hematocrit (proportion of 1), Male: 0.404-0.519, Female: 0.343-0.452.
| participants | Lamotrigine |
|---|---|
| Total protein, High, Week 0; n=92 | 1 |
| Total protein, Normal, Week 0; n=92 | 85 |
| Total protein, Low, Week 0; n=92 | 6 |
| Total protein, High, Week 6; n=84 | 0 |
| Total protein, Normal, Week 6; n=84 | 77 |
| Total protein, Low, Week 6; n=84 | 7 |
| Total protein, High, Week 16; n=78 | 0 |
| Total protein, Normal, Week 16; n=78 | 74 |
| Total protein, Low, Week 16; n=78 | 4 |
| Total protein, High, Week 28; n=77 | 0 |
| Total protein, Normal, Week 28; n=77 | 69 |
| Total protein, Low, Week 28; n=77 | 8 |
| Total protein, High, Week 40; n=70 | 1 |
| Total protein, Normal, Week 40; n=70 | 64 |
| Total protein, Low, Week 40; n=70 | 5 |
| Total protein, High, Week 52/EW; n=86 | 0 |
| Total protein, Normal, Week 52/EW; n=86 | 72 |
| Total protein, Low, Week 52/EW; n=86 | 14 |
| Hemoglobin, High, Week 0; n=92 | 4 |
| Hemoglobin, Normal, Week 0; n=92 | 80 |
| Hemoglobin, Low, Week 0; n=92 | 8 |
| Hemoglobin, High, Week 6; n=84 | 2 |
| Hemoglobin, Normal, Week 6; n=84 | 75 |
| Hemoglobin, Low, Week 6; n=84 | 7 |
| Hemoglobin, High, Week 16; n=78 | 3 |
| Hemoglobin, Normal, Week 16; n=78 | 68 |
| Hemoglobin, Low, Week 16; n=78 | 7 |
| Hemoglobin, High, Week 28; n=77 | 1 |
| Hemoglobin, Normal, Week 28; n=77 | 69 |
| Hemoglobin, Low, Week 28; n=77 | 7 |
| Hemoglobin, High, Week 40; n=69 | 1 |
| Hemoglobin, Normal, Week 40; n=69 | 62 |
| Hemoglobin, Low, Week 40; n=69 | 6 |
| Hemoglobin, High, Week 52/EW; n=86 | 4 |
| Hemoglobin, Normal, Week 52/EW; n=86 | 71 |
| Hemoglobin, Low, Week 52/EW; n=86 | 11 |
| Hematocrit, High, Week 0; n=92 | 4 |
| Hematocrit, Normal, Week 0; n=92 | 83 |
| Hematocrit, Low, Week 0; n=92 | 5 |
| Hematocrit, High, Week 6; n=84 | 3 |
| Hematocrit, Normal, Week 6; n=84 | 75 |
| Hematocrit, Low, Week 6; n=84 | 6 |
| Hematocrit, High, Week 16; n=78 | 2 |
| Hematocrit, Normal, Week 16; n=78 | 73 |
| Hematocrit, Low, Week 16; n=78 | 3 |
| Hematocrit, High, Week 28; n=77 | 3 |
| Hematocrit, Normal, Week 28; n=77 | 69 |
| Hematocrit, Low, Week 28; n=77 | 5 |
| Hematocrit, High, Week 40; n=69 | 4 |
| Hematocrit, Normal, Week 40; n=69 | 63 |
| Hematocrit, Low, Week 40; n=69 | 2 |
| Hematocrit, High, Week 52/EW; n=86 | 3 |
| Hematocrit, Normal, Week 52/EW; n=86 | 73 |
| Hematocrit, Low, Week 52/EW; n=86 | 10 |
Red blood cell count was measured in participants at the indicated time points. Participants were categorized as "High" for laboratory values above normal (reference) and as "Low" for laboratory values below normal ranges used by the central laboratory. Normal ranges: red blood cell count, Male: 4.38-5.77 TI (tebi; 10\^12)/L, Female: 3.76-5.16 TI/L.
| participants | Lamotrigine |
|---|---|
| Red blood cell count, High, Week 0; n=92 | 2 |
| Red blood cell count, Normal, Week 0; n=92 | 88 |
| Red blood cell count, Low, Week 0; n=92 | 2 |
| Red blood cell count, High, Week 6; n=84 | 1 |
| Red blood cell count, Normal, Week 6; n=84 | 78 |
| Red blood cell count, Low, Week 6; n=84 | 5 |
| Red blood cell count, High, Week 16; n=78 | 1 |
| Red blood cell count, Normal, Week 16; n=78 | 73 |
| Red blood cell count, Low, Week 16; n=78 | 4 |
| Red blood cell count, High, Week 28; n=77 | 1 |
| Red blood cell count, Normal, Week 28; n=77 | 70 |
| Red blood cell count, Low, Week 28; n=77 | 6 |
| Red blood cell count, High, Week 40; n=69 | 1 |
| Red blood cell count, Normal, Week 40; n=69 | 64 |
| Red blood cell count, Low, Week 40; n=69 | 4 |
| Red blood cell count, High, Week 52/EW; n=86 | 3 |
| Red blood cell count, Normal, Week 52/EW; n=86 | 72 |
| Red blood cell count, Low, Week 52/EW; n=86 | 11 |
Urine glucose, urine protein, and urine urobilinogen were measured in participants at the indicated time points. In this dipstick (qualitative) test, the level of glucose, protein, and urobilinogen in urine samples was recorded as negative (NEG \[-\]), trace (TRA \[+/-\]), 1+, 2+, 3+, 4+, and 5+ (the plus sign increases with a higher level of glucose, protein, or urobilinogen in the urine: 1+=slightly positive, 2+=positive, 3+=high positive, 4+=very high positive, 5+=more positive than 4+).
| participants | Lamotrigine |
|---|---|
| Urine Glucose, Week 0, NEG [-]; n=92 | 88 |
| Urine Glucose, Week 0, TRA [+/-]; n=92 | 1 |
| Urine Glucose, Week 0, 1+; n=92 | 1 |
| Urine Glucose, Week 0, 2+; n=92 | 1 |
| Urine Glucose, Week 0, 3+; n=92 | 0 |
| Urine Glucose, Week 0, 4+; n=92 | 1 |
| Urine Glucose, Week 0, 5+; n=92 | 0 |
| Urine Glucose, Week 6, NEG [-]; n=84 | 81 |
| Urine Glucose, Week 6, TRA [+/-]; n=84 | 0 |
| Urine Glucose, Week 6, 1+; n=84 | 1 |
| Urine Glucose, Week 6, 2+; n=84 | 1 |
| Urine Glucose, Week 6, 3+; n=84 | 1 |
| Urine Glucose, Week 6, 4+; n=84 | 0 |
| Urine Glucose, Week 6, 5+; n=84 | 0 |
| Urine Glucose, Week 16, NEG [-]; n=78 | 77 |
| Urine Glucose, Week 16, TRA [+/-]; n=78 | 0 |
| Urine Glucose, Week 16, 1+; n=78 | 1 |
| Urine Glucose, Week 16, 2+; n=78 | 0 |
| Urine Glucose, Week 16, 3+; n=78 | 0 |
| Urine Glucose, Week 16, 4+; n=78 | 0 |
| Urine Glucose, Week 16, 5+; n=78 | 0 |
| Urine Glucose, Week 28, NEG [-]; n=77 | 76 |
| Urine Glucose, Week 28, TRA [+/-]; n=77 | 1 |
| Urine Glucose, Week 28, 1+; n=77 | 0 |
| Urine Glucose, Week 28, 2+; n=77 | 0 |
| Urine Glucose, Week 28, 3+; n=77 | 0 |
| Urine Glucose, Week 28, 4+; n=77 | 0 |
| Urine Glucose, Week 28, 5+; n=77 | 0 |
| Urine Glucose, Week 40, NEG [-]; n=70 | 68 |
| Urine Glucose, Week 40, TRA [+/-]; n=70 | 2 |
| Urine Glucose, Week 40, 1+; n=70 | 0 |
| Urine Glucose, Week 40, 2+; n=70 | 0 |
| Urine Glucose, Week 40, 3+; n=70 | 0 |
| Urine Glucose, Week 40, 4+; n=70 | 0 |
| Urine Glucose, Week 40, 5+; n=70 | 0 |
| Urine Glucose, Week 52/EW, NEG [-]; n=86 | 85 |
| Urine Glucose, Week 52/EW, TRA [+/-]; n=86 | 0 |
| Urine Glucose, Week 52/EW, 1+; n=86 | 1 |
| Urine Glucose, Week 52/EW, 2+; n=86 | 0 |
| Urine Glucose, Week 52/EW, 3+; n=86 | 0 |
| Urine Glucose, Week 52/EW, 4+; n=86 | 0 |
| Urine Glucose, Week 52/EW, 5+; n=86 | 0 |
| Urine Protein, Week 0, NEG [-]; n=92 | 87 |
| Urine Protein, Week 0, TRA [+/-]; n=92 | 3 |
| Urine Protein, Week 0, 1+; n=92 | 1 |
| Urine Protein, Week 0, 2+; n=92 | 1 |
| Urine Protein, Week 0, 3+; n=92 | 0 |
| Urine Protein, Week 0, 4+; n=92 | 0 |
| Urine Protein, Week 0, 5+; n=92 | 0 |
| Urine Protein, Week 6, NEG [-]; n=84 | 81 |
| Urine Protein, Week 6, TRA [+/-]; n=84 | 1 |
| Urine Protein, Week 6, 1+; n=84 | 2 |
| Urine Protein, Week 6, 2+; n=84 | 0 |
| Urine Protein, Week 6, 3+; n=84 | 0 |
| Urine Protein, Week 6, 4+; n=84 | 0 |
| Urine Protein, Week 6, 5+; n=84 | 0 |
| Urine Protein, Week 16, NEG [-]; n=78 | 76 |
| Urine Protein, Week 16, TRA [+/-]; n=78 | 0 |
| Urine Protein, Week 16, 1+; n=78 | 1 |
| Urine Protein, Week 16, 2+; n=78 | 1 |
| Urine Protein, Week 16, 3+; n=78 | 0 |
| Urine Protein, Week 16, 4+; n=78 | 0 |
| Urine Protein, Week 16, 5+; n=78 | 0 |
| Urine Protein, Week 28, NEG [-]; n=77 | 75 |
| Urine Protein, Week 28, TRA [+/-]; n=77 | 0 |
| Urine Protein, Week 28, 1+; n=77 | 2 |
| Urine Protein, Week 28, 2+; n=77 | 0 |
| Urine Protein, Week 28, 3+; n=77 | 0 |
| Urine Protein, Week 28, 4+; n=77 | 0 |
| Urine Protein, Week 28, 5+; n=77 | 0 |
| Urine Protein, Week 40, NEG [-]; n=70 | 69 |
| Urine Protein, Week 40, TRA [+/-]; n=70 | 0 |
| Urine Protein, Week 40, 1+; n=70 | 0 |
| Urine Protein, Week 40, 2+; n=70 | 1 |
| Urine Protein, Week 40, 3+; n=70 | 0 |
| Urine Protein, Week 40, 4+; n=70 | 0 |
| Urine Protein, Week 40, 5+; n=70 | 0 |
| Urine Protein, Week 52/EW, NEG [-]; n=86 | 81 |
| Urine Protein, Week 52/EW, TRA [+/-]; n=86 | 1 |
| Urine Protein, Week 52/EW, 1+; n=86 | 3 |
| Urine Protein, Week 52/EW, 2+; n=86 | 1 |
| Urine Protein, Week 52/EW, 3+; n=86 | 0 |
| Urine Protein, Week 52/EW, 4+; n=86 | 0 |
| Urine Protein, Week 52/EW, 5+; n=86 | 0 |
| Urine Urobilinogen, Week 0, NEG [-]; n=92 | 0 |
| Urine Urobilinogen, Week 0, TRA [+/-]; n=92 | 88 |
| Urine Urobilinogen, Week 0, 1+; n=92 | 4 |
| Urine Urobilinogen, Week 0, 2+; n=92 | 0 |
| Urine Urobilinogen, Week 0, 3+; n=92 | 0 |
| Urine Urobilinogen, Week 0, 4+; n=92 | 0 |
| Urine Urobilinogen, Week 0, 5+; n=92 | 0 |
| Urine Urobilinogen, Week 6, NEG [-]; n=84 | 0 |
| Urine Urobilinogen, Week 6, TRA [+/-]; n=84 | 81 |
| Urine Urobilinogen, Week 6, 1+; n=84 | 2 |
| Urine Urobilinogen, Week 6, 2+; n=84 | 1 |
| Urine Urobilinogen, Week 6, 3+; n=84 | 0 |
| Urine Urobilinogen, Week 6, 4+; n=84 | 0 |
| Urine Urobilinogen, Week 6, 5+; n=84 | 0 |
| Urine Urobilinogen, Week 16, NEG [-]; n=78 | 0 |
| Urine Urobilinogen, Week 16, TRA [+/-]; n=78 | 76 |
| Urine Urobilinogen, Week 16, 1+; n=78 | 2 |
| Urine Urobilinogen, Week 16, 2+; n=78 | 0 |
| Urine Urobilinogen, Week 16, 3+; n=78 | 0 |
| Urine Urobilinogen, Week 16, 4+; n=78 | 0 |
| Urine Urobilinogen, Week 16, 5+; n=78 | 0 |
| Urine Urobilinogen, Week 28, NEG [-]; n=77 | 0 |
| Urine Urobilinogen, Week 28, TRA [+/-]; n=77 | 77 |
| Urine Urobilinogen, Week 28, 1+; n=77 | 0 |
| Urine Urobilinogen, Week 28, 2+; n=77 | 0 |
| Urine Urobilinogen, Week 28, 3+; n=77 | 0 |
| Urine Urobilinogen, Week 28, 4+; n=77 | 0 |
| Urine Urobilinogen, Week 28, 5+; n=77 | 0 |
| Urine Urobilinogen, Week 40, NEG [-]; n=70 | 0 |
| Urine Urobilinogen, Week 40, TRA [+/-]; n=70 | 68 |
| Urine Urobilinogen, Week 40, 1+; n=70 | 2 |
| Urine Urobilinogen, Week 40, 2+; n=70 | 0 |
| Urine Urobilinogen, Week 40, 3+; n=70 | 0 |
| Urine Urobilinogen, Week 40, 4+; n=70 | 0 |
| Urine Urobilinogen, Week 40, 5+; n=70 | 0 |
| Urine Urobilinogen, Week 52/EW, NEG [-]; n=86 | 0 |
| Urine Urobilinogen, Week 52/EW, TRA [+/-]; n=86 | 82 |
| Urine Urobilinogen, Week 52/EW, 1+; n=86 | 4 |
| Urine Urobilinogen, Week 52/EW, 2+; n=86 | 0 |
| Urine Urobilinogen, Week 52/EW, 3+; n=86 | 0 |
| Urine Urobilinogen, Week 52/EW, 4+; n=86 | 0 |
| Urine Urobilinogen, Week 52/EW, 5+; n=86 | 0 |
Systolic and diastolic blood pressure was measured in participants at the indicated time points.
| Millimeters of mercury | Lamotrigine |
|---|---|
| Systolic blood pressure, Week 0; n=92 | 119.9 ± 15.40 |
| Systolic blood pressure, Week 2; n=87 | 121.7 ± 16.11 |
| Systolic blood pressure, Week 4; n=85 | 118.9 ± 15.77 |
| Systolic blood pressure, Week 5; n=85 | 119.0 ± 16.26 |
| Systolic blood pressure, Week 6; n=84 | 120.4 ± 16.09 |
| Systolic blood pressure, Week 8; n=81 | 118.6 ± 16.28 |
| Systolic blood pressure, Week 12; n=79 | 120.1 ± 15.71 |
| Systolic blood pressure, Week 16; n=78 | 119.1 ± 16.76 |
| Systolic blood pressure, Week 20; n=77 | 117.8 ± 15.04 |
| Systolic blood pressure, Week 24; n=77 | 118.5 ± 15.30 |
| Systolic blood pressure, Week 28; n=77 | 117.3 ± 18.84 |
| Systolic blood pressure, Week 32; n=76 | 121.8 ± 17.04 |
| Systolic blood pressure, Week 36; n=73 | 121.3 ± 15.80 |
| Systolic blood pressure, Week 40; n=70 | 118.2 ± 15.21 |
| Systolic blood pressure, Week 44; n=69 | 118.7 ± 14.88 |
| Systolic blood pressure, Week 48; n=69 | 121.2 ± 16.37 |
| Systolic blood pressure, Week 52/EW; n=87 | 118.2 ± 14.20 |
| Diastolic blood pressure, Week 0; n=92 | 74.2 ± 11.41 |
| Diastolic blood pressure, Week 2; n=87 | 74.9 ± 11.62 |
| Diastolic blood pressure, Week 4; n=85 | 74.2 ± 12.08 |
| Diastolic blood pressure, Week 5; n=85 | 73.8 ± 12.34 |
| Diastolic blood pressure, Week 6; n=84 | 73.7 ± 11.16 |
| Diastolic blood pressure, Week 8; n=81 | 72.6 ± 12.72 |
| Diastolic blood pressure, Week 12; n=79 | 73.2 ± 12.08 |
| Diastolic blood pressure, Week 16; n=78 | 73.0 ± 12.29 |
| Diastolic blood pressure, Week 20; n=77 | 73.6 ± 11.59 |
| Diastolic blood pressure, Week 24; n=77 | 74.2 ± 11.72 |
| Diastolic blood pressure, Week 28; n=77 | 71.1 ± 12.24 |
| Diastolic blood pressure, Week 32; n=76 | 74.0 ± 11.93 |
| Diastolic blood pressure, Week 36; n=73 | 72.4 ± 10.98 |
| Diastolic blood pressure, Week 40; n=70 | 72.3 ± 12.04 |
| Diastolic blood pressure, Week 44; n=69 | 73.0 ± 12.22 |
| Diastolic blood pressure, Week 48; n=69 | 72.7 ± 11.91 |
| Diastolic blood pressure, Week 52/EW; n=87 | 73.2 ± 11.69 |
Heart rate was measured in participants at the indicated time points.
| beat per minute | Lamotrigine |
|---|---|
| Week 0; n=92 | 76.3 ± 12.48 |
| Week 2; n=87 | 78.0 ± 12.77 |
| Week 4; n=85 | 77.4 ± 11.96 |
| Week 5; n=85 | 78.5 ± 12.54 |
| Week 6; n=84 | 77.0 ± 11.97 |
| Week 8; n=81 | 76.8 ± 11.34 |
| Week 12; n=79 | 79.0 ± 13.47 |
| Week 16; n=78 | 76.5 ± 11.81 |
| Week 20; n=77 | 77.4 ± 11.09 |
| Week 24; n=77 | 74.9 ± 12.50 |
| Week 28; n=77 | 75.9 ± 10.28 |
| Week 32; n=76 | 77.2 ± 12.23 |
| Week 36; n=73 | 76.8 ± 11.46 |
| Week 40; n=70 | 75.8 ± 10.63 |
| Week 44; n=69 | 77.3 ± 11.10 |
| Week 48; n=69 | 78.2 ± 11.63 |
| Week 52/EW; n=87 | 74.8 ± 11.75 |
The weight of participants was recorded at the indicated time points.
| kilograms | Lamotrigine |
|---|---|
| Week 0; n=92 | 60.86 ± 12.532 |
| Week 6; n=84 | 61.62 ± 12.405 |
| Week 8; n=81 | 61.29 ± 12.420 |
| Week 12; n=79 | 61.26 ± 12.685 |
| Week 16; n=78 | 61.38 ± 12.753 |
| Week 20; n=77 | 61.19 ± 12.929 |
| Week 24; n=77 | 61.29 ± 12.712 |
| Week 28; n=77 | 60.99 ± 12.688 |
| Week 32; n=76 | 61.05 ± 12.840 |
| Week 36; n=73 | 61.06 ± 13.097 |
| Week 40; n=70 | 60.67 ± 13.214 |
| Week 44; n=69 | 60.72 ± 13.214 |
| Week 48; n=69 | 60.43 ± 13.056 |
| Week 52/EW; n=87 | 60.09 ± 12.765 |
The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared.
| Kilograms per meters squared | Lamotrigine |
|---|---|
| Week 0; n=92 | 22.8 ± 3.934 |
| Week 6; n=84 | 23.01 ± 3.878 |
| Week 8; n=81 | 22.89 ± 3.863 |
| Week 12; n=79 | 22.93 ± 3.975 |
| Week 16; n=78 | 22.96 ± 3.965 |
| Week 20; n=77 | 22.86 ± 3.941 |
| Week 24; n=77 | 22.91 ± 3.916 |
| Week 28; n=77 | 22.80 ± 3.970 |
| Week 32; n=76 | 22.81 ± 4.016 |
| Week 36; n=73 | 22.71 ± 4.041 |
| Week 40; n=70 | 22.48 ± 3.820 |
| Week 44; n=69 | 22.51 ± 3.785 |
| Week 48; n=69 | 22.40 ± 3.750 |
| Week 52/EW; n=87 | 22.42 ± 3.818 |
ECGs were recorded in participants at the indicated time points. ECG findings, as determined by the physicians, were reported as normal, abnormal but not clinically significant (NCS), abnormal but clinically significant (CS), and no result. Specific definitions of ECG categorizations were not provided; physicians were expected to apply reasonable standards of clinical judgment.
| participants | Lamotrigine |
|---|---|
| Week 0, Normal; n=92 | 73 |
| Week 0, Abnormal-NCS; n=92 | 19 |
| Week 0, Abnormal-CS; n=92 | 0 |
| Week 0, No result; n=92 | 0 |
| Week 6, Normal; n=84 | 69 |
| Week 6, Abnormal-NCS; n=84 | 15 |
| Week 6, Abnormal-CS; n=84 | 0 |
| Week 6, No result; n=84 | 0 |
| Week 28, Normal; n=77 | 62 |
| Week 28, Abnormal-NCS; n=77 | 15 |
| Week 28, Abnormal-CS; n=77 | 0 |
| Week 28, No result; n=77 | 0 |
| Week 52 (EW), Normal; n=84 | 68 |
| Week 52 (EW), Abnormal-NCS; n=84 | 15 |
| Week 52 (EW), Abnormal-CS; n=84 | 1 |
| Week 52 (EW), No result; n=84 | 0 |
The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. The number of participants with an assessment varied depending on the number of assessments completed at each visit (indicated time points).
| scores on a scale | Lamotrigine |
|---|---|
| Week 0, LOCF; n=92 | 2.9 ± 1.10 |
| Week 0, OC; n=92 | 2.9 ± 1.10 |
| Week 2, LOCF; n=91 | 2.6 ± 1.19 |
| Week 2, OC; n=87 | 2.5 ± 1.13 |
| Week 4, LOCF; n=92 | 2.5 ± 1.17 |
| Week 4, OC; n=85 | 2.3 ± 0.98 |
| Week 5, LOCF; n=92 | 2.4 ± 1.16 |
| Week 5, OC; n=85 | 2.2 ± 0.95 |
| Week 6, LOCF; n=92 | 2.3 ± 1.13 |
| Week 6, OC; n=84 | 2.2 ± 0.89 |
| Week 8, LOCF; n=92 | 2.4 ± 1.16 |
| Week 8, OC; n=81 | 2.2 ± 0.93 |
| Week 12, LOCF; n=92 | 2.2 ± 1.20 |
| Week 12, OC; n=79 | 2.0 ± 0.91 |
| Week 16, LOCF; n=92 | 2.3 ± 1.21 |
| Week 16, OC; n=78 | 2.1 ± 0.94 |
| Week 20, LOCF; n=92 | 2.4 ± 1.22 |
| Week 20, OC; n=77 | 2.1 ± 0.96 |
| Week 24, LOCF; n=92 | 2.4 ± 1.20 |
| Week 24, OC; n=77 | 2.2 ± 0.95 |
| Week 28, LOCF; n=92 | 2.3 ± 1.24 |
| Week 28, OC; n=77 | 2.1 ± 0.99 |
| Week 32, LOCF; n=92 | 2.4 ± 1.19 |
| Week 32, OC; n=76 | 2.2 ± 0.93 |
| Week 36, LOCF; n=92 | 2.3 ± 1.23 |
| Week 36, OC; n=73 | 2.0 ± 0.95 |
| Week 40, LOCF; n=92 | 2.4 ± 1.22 |
| Week 40, OC; n=70 | 2.1 ± 0.95 |
| Week 44, LOCF; n=92 | 2.4 ± 1.23 |
| Week 44, OC; n=69 | 2.1 ± 0.93 |
| Week 48, LOCF; n=92 | 2.3 ± 1.23 |
| Week 48, OC; n=69 | 2.0 ± 0.91 |
| Week 52/EW, LOCF; n=92 | 2.1 ± 1.24 |
| Week 52/EW, OC; n=87 | 2.1 ± 1.25 |
The CGI-S is a standardized assessment tool that uses a 7-point scale to assess a participant's severity of illness. The total score ranges from 0 to 7: 0=not assessed, 1=normal, 2=borderline ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severly ill, 7=extremely ill. Higher scores reflect a higher severity of current illness states. Change from baseline was calculated as the values at Weeks 2, 4, 5, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52 (or EW) minus the baseline value (Week 0).
| scores on a scale | Lamotrigine |
|---|---|
| Week 2, LOCF; n=91 | -0.3 ± 0.93 |
| Week 2, OC; n=87 | -0.3 ± 0.92 |
| Week 4, LOCF; n=92 | -0.4 ± 1.01 |
| Week 4, OC; n=85 | -0.5 ± 0.96 |
| Week 5, LOCF; n=92 | -0.5 ± 1.07 |
| Week 5, LOCF; n=85 | -0.6 ± 1.03 |
| Week 6, LOCF; n=92 | -0.6 ± 1.07 |
| Week 6, OC; n=84 | -0.7 ± 1.02 |
| Week 8, LOCF; n=92 | -0.5 ± 1.16 |
| Week 8, LOCF; n=81 | -0.6 ± 1.14 |
| Week 12, LOCF; n=92 | -0.7 ± 1.23 |
| Week 12, OC; n=79 | -0.8 ± 1.19 |
| Week 16, LOCF; n=92 | -0.6 ± 1.21 |
| Week 16, OC; n=78 | -0.7 ± 1.17 |
| Week 20, LOCF; n=92 | -0.5 ± 1.17 |
| Week 20, OC; n=77 | -0.6 ± 1.14 |
| Week 24, LOCF; n=92 | -0.5 ± 1.09 |
| Week 24, OC; n=77 | -0.6 ± 1.05 |
| Week 28, LOCF; n=92 | -0.5 ± 1.23 |
| Week 28, OC; n=77 | -0.7 ± 1.21 |
| Week 32, LOCF; n=92 | -0.5 ± 1.14 |
| Week 32, OC; n=76 | -0.6 ± 1.11 |
| Week 36, LOCF; n=92 | -0.6 ± 1.18 |
| Week 36, OC; n=73 | -0.7 ± 1.13 |
| Week 40, LOCF; n=92 | -0.5 ± 1.24 |
| Week 40, OC; n=70 | -0.6 ± 1.22 |
| Week 44, LOCF; n=92 | -0.5 ± 1.16 |
| Week 44, OC; n=69 | -0.6 ± 1.11 |
| Week 48, LOCF; n=92 | -0.6 ± 1.19 |
| Week 48, OC; n=69 | -0.7 ± 1.14 |
| Week 52/EW, LOCF; n=92 | -0.8 ± 1.19 |
| Week 52/EW, OC; n=87 | -0.8 ± 1.19 |
The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill).
| scores on a scale | Lamotrigine |
|---|---|
| Week 6, LOCF; n=91 | 5.2 ± 6.68 |
| Week 6, OC; n=84 | 4.3 ± 4.85 |
| Week 16, LOCF; n=91 | 6.1 ± 7.28 |
| Week 16, OC; n=78 | 5.2 ± 6.01 |
| Week 28, LOCF; n=91 | 5.5 ± 6.76 |
| Week 28, OC; n=77 | 4.5 ± 5.13 |
| Week 40, LOCF; n=91 | 5.9 ± 7.21 |
| Week 40, OC; n=70 | 4.7 ± 5.53 |
| Week 52/EW, LOCF; n=91 | 5.5 ± 7.30 |
| Week 52/EW, OC; n=87 | 5.4 ± 7.38 |
The HAMD-17 is a 17-item questionnaire that detects change and measures illness severity. Individual items were rated on a scale of 0-4 and 0-2, with the total HAMD-17 score ranging from 0 (not ill) to 52 (severely ill). Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).
| scores on a scale | Lamotrigine |
|---|---|
| Week 6, LOCF; n=91 | -4.5 ± 7.37 |
| Week 6, OC; n=84 | -4.7 ± 7.19 |
| Week 16, LOCF; n=91 | -3.7 ± 7.51 |
| Week 16, OC; n=78 | -3.8 ± 7.51 |
| Week 28, LOCF; n=91 | -4.3 ± 7.62 |
| Week 28, OC; n=77 | -4.5 ± 7.66 |
| Week 40, LOCF; n=91 | -3.9 ± 7.77 |
| Week 40, OC; n=70 | -3.9 ± 7.69 |
| Week 52/EW, LOCF; n=91 | -4.3 ± 7.17 |
| Week 52/EW, OC; n=87 | -4.1 ± 6.96 |
The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. For all items, 0 is the "best" rating and 4 or 8 is the "worst" rating. YMRS total score was computed as the sum of the scores for the 11 items on the scale. The possible total scores range from 0 (best) to 60 (worst).
| scores on a scale | Lamotrigine |
|---|---|
| Week 6, LOCF; n=91 | 3.2 ± 6.20 |
| Week 6, OC; n=84 | 2.6 ± 4.37 |
| Week 16, LOCF; n=91 | 2.6 ± 5.83 |
| Week 16, OC; n=78 | 1.7 ± 3.02 |
| Week 28, LOCF; n=91 | 2.8 ± 6.96 |
| Week 28, OC; n=77 | 2.0 ± 5.19 |
| Week 40, LOCF; n=91 | 2.7 ± 6.24 |
| Week 40, OC; n=70 | 1.7 ± 3.95 |
| Week 52/EW, LOCF; n=91 | 1.9 ± 5.55 |
| Week 52/EW, OC; n=87 | 2.0 ± 5.66 |
The YMRS is an 11-item, multiple-choice diagnostic questionnaire used to measure the severity of disease in participants. Individual items (1=elevated mood, 2=increased motor activity, 3=sexual interest, 4=sleep, 5=irritability, 6=speech, 7=language thought disorder, 8=content, 9=disruptive aggressive behaviour, 10=appearance, 11=insight) were rated on a scale of 0-4 and 0-8. YMRS total score (range of 0-60) was computed as sum of the scores for the 11 items on the scale. Change from baseline was calculated as the values at Week 6, 16, 28, 40, and 52 (or EW) minus the baseline value (Week 0).
| scores on a scale | Lamotrigine |
|---|---|
| Week 6, LOCF; n=91 | 0.2 ± 6.64 |
| Week 6, OC; n=84 | -0.3 ± 5.88 |
| Week 16, LOCF; n=91 | -0.4 ± 7.20 |
| Week 16, OC; n=78 | -1.3 ± 6.13 |
| Week 28, LOCF; n=91 | -0.2 ± 6.89 |
| Week 28, OC; n=77 | -1.1 ± 5.75 |
| Week 40, LOCF; n=91 | -0.3 ± 7.56 |
| Week 40, OC; n=70 | -1.1 ± 6.73 |
| Week 52/EW, LOCF; n=91 | -1.1 ± 7.11 |
| Week 52/EW, OC; n=87 | -1.1 ± 7.27 |
Pharmacokinetic (PK) samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.
| Nanograms per milliliter | Lamotrigine |
|---|---|
| Median Serum Lamotrigine 200 mg Concentration Among Participants With Concomitant Use of Inducer and Without Inhibitor (at the Timing of Blood Sample Collection) | 1605.70 (0.00 to 3238.6) |
PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.
| Nanograms per milliliter | Lamotrigine |
|---|---|
| Lamotrigine 100 mg; n=5 | 5312.30 (3762.7 to 15107.0) |
| Lamotrigine 200 mg; n=4 | 6935.40 (3210.2 to 9300.9) |
PK samples were collected at Weeks 6, 16, 28, 40, 52/EW, and the plasma lamotrigine concentrations were measured. Participants were required to visit the study site without taking the investigational product on the morning of the PK blood sampling. Inhibitors are defined as drugs that inhibit lamotrigine glucuronidation (i.e., valproate). Inducers are defined as drugs that induce lamotrigine glucuronidation (e.g., carbamazepine). The median value presented is the median of all samples collected at Weeks 6, 16, 28, 40, and 52/EW.
| Nanograms per milliliter | Lamotrigine |
|---|---|
| Lamotrigine 25 mg; n=2 | 699.95 (527.8 to 872.1) |
| Lamotrigine 100 mg; n=12 | 2793.55 (1486.7 to 7440.8) |
| Lamotrigine 125 mg; n=1 | 3505.30 (3505.3 to 3505.3) |
| Lamotrigine 150 mg; n=1 | 5418.40 (5418.4 to 5418.4) |
| Lamotrigine 200 mg; n=78 | 4092.30 (131.0 to 11053.2) |
| Lamotrigine 225 mg; n=1 | 3594.25 (2879.3 to 4309.2) |
| Lamotrigine 300 mg; n=7 | 5127.10 (3349.4 to 12066.6) |
| Lamotrigine 400 mg; n=4 | 8600.40 (4722.2 to 10830.3) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lamotrigine | — | 13/92 (14.1%) | 52/92 (56.5%) |
| Event | Lamotrigine |
|---|---|
| ManiaPsychiatric disorders | 4/92 |
| DepressionPsychiatric disorders | 2/92 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/92 |
| DeliriumPsychiatric disorders | 1/92 |
| Self injurious behaviourPsychiatric disorders | 1/92 |
| Suicidal ideationPsychiatric disorders | 1/92 |
| Sick sinus syndromeCardiac disorders | 1/92 |
| PharyngitisInfections and infestations | 1/92 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/92 |
| Ovarian hemorrhageReproductive system and breast disorders | 1/92 |
| Event | Lamotrigine |
|---|---|
| NasopharyngitisInfections and infestations | 36/92 |
| Abdominal pain upperGastrointestinal disorders | 14/92 |
| StomatitisGastrointestinal disorders | 11/92 |
| NauseaGastrointestinal disorders | 7/92 |
| VomitingGastrointestinal disorders | 7/92 |
| DiarrheaGastrointestinal disorders | 6/92 |
| HeadacheNervous system disorders | 6/92 |
| AnemiaBlood and lymphatic system disorders | 5/92 |
| Back painMusculoskeletal and connective tissue disorders | 5/92 |
| Age, Continuous(Years) | Lamotrigine |
|---|---|
| Mean | 43.5 ± 12.11 |
| Sex: Female, Male(Participants) | Lamotrigine |
|---|---|
| Female | 52 |
| Male | 40 |
| Race/Ethnicity, Customized(participants) | Lamotrigine |
|---|---|
| Asian - Japanese Heritage | 91 |
| Asian - East Asian Heritage | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine